Resolution of FDA issues a key positive for the stock and should be sorted in FY16, so investors should be patient
Expectation of advertising recovery and subscription growth are positives but weakening position a worry
Analysts say correction is overdone; price rise for OTC drugs could reduce impact
Analysts however say that the correction is overdone, stock reverses direction, recoups some losses
Its acquisition of Germany-based Scherer and Trier is complementary with its other plastic parts' subsidiary SMP
New launches, a strong US pipeline and high-growth India operations justify the premium valuations
Near-term concerns on spectrum and data pricing, but execution and attractive valuations make it a good bet
Company expected to post double-digit growth on product launches and good demand for entry-level cars
Resolution of US FDA issues key trigger for the stock
Merger with Shasun, tie-ups could mean higher profits
Expect higher profit growth as the entire raw material basket of prices tumbles
Falling fuel costs and higher demand are huge positives but pricing indiscipline the biggest risk
Positive outlook leads to an upgrade in volume estimates
Most analysts are not very bullish on upstream companies
Recent launches, strong portfolio in limited-competition categories should aid revenue and margins
Steep drop in natural rubber prices aids margins, net profit
Spectrum auctions, improvement in African operations are key triggers for the stock
The portfolio holds significant promise and can add to the strong domestic performance
Rise in competition could offset gains on falling fuel prices; for SpiceJet, a turnround hangs on recapitalisation
Given lower volume forecast, higher expenses, margins are likely to remain at current levels for next few quarters